ClinicalTrials.gg
CompletedNCT03198078Updated Dec 20, 2023Results posted

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

A Phase 3 interventional study of Brexpiprazole (OPC-34712) and Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
9th of 28
316 · median 155
Started
2017
with 1 other
Phase 3
16 of 28
none open now
Registered
23rd of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 3, and was the 23rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 13 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo- and active-controlled trial to evaluate the safety and efficacy of brexpiprazole monotherapy compared to placebo in adolescent subjects (ages 13-17) with a DSM-5 diagnosis of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Brexpiprazole
  • Schizophrenia
  • Adolescent
04

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male \& female subjects aged 13-17 years, inclusive at time of consent and at baseline visit, with a primary diagnosis of schizophrenia as defined by criteria and confirmed by K-SADS-PL and a history of the illness for at least 6 months prior to screening.
  • PANSS score >= 80, inclusive, at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Subjects with a diagnosis other than schizophrenia that has been the primary focus of treatment within 3 months of screening.
  • Subjects with a clinical presentation or history that is consistent with delirium, dementia, amnesia or other cognitive disorders
  • Subjects who have been hospitalized > 21 days for a current exacerbation of schizophrenia at the time of baseline.
  • Any neurological disorder other than Tourette's Syndrome
  • Subjects at significant risk of committing violent acts, serious self-harm or suicide based on history
  • Subjects with epilepsy, a history of seizures, severe head trauma or stroke
  • Subjects who test positive for drugs of abuse at screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Participants were administered with brexpiprazole oral tablets, daily, dose titrated up to 0.5 mg by Day 4, 1 mg by Day 7, 2 mg by Day 14, then between 2-4 mg after Day 21 up to Week 6 with a 1 mg increase or decrease, based on the Investigator's decision.

    Drug: Brexpiprazole (OPC-34712)

  • Active comparator
    Aripiprazole

    Participants were administered with aripiprazole oral tablets, daily, dose titrated up to 2 mg by Day 4, 5 mg by Day 7, 10 mg by Day 14, then 10, 15 or 20 mg after Day 21 up to Week 6 with a 5 mg increase or decrease, based on the Investigator's decision.

    Drug: Aripiprazole

  • Placebo comparator
    Placebo

    Participants were administered with brexpiprazole or aripiprazole matching placebo oral tablets, daily up to Week 6.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) to 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worsening of symptoms. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value and baseline visit interaction as a covariate, and with an unstructured covariance.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in PANSS Positive and Negative Sub-Scales Scores

    PANSS has 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility; and 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). PANSS positive \& negative subscale scores were the sum of rating scores for 7 positive \& 7 negative items respectively. Both scores range from 7 (best possible outcome) to 49 (worst possible outcome). Higher scores denote worsening of symptoms. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

    Time frame: Baseline to Week 6

  2. Percentage of Participants Achieving Response

    Response was defined as at least 30% improvement from baseline in PANSS Total Score or CGI score of 1 or 2. The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel, and ranges from 30 (best possible outcome) to 210 (worst possible outcome). The CGI scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Percentage of participants achieving response was determined by Last Observation Carried Forward (LOCF) method.

    Time frame: Up to 6 weeks

  3. Percentage of Participants Achieving Remission

    Remission was defined as a score of ≤ 3 on each of the following specific PANSS items: delusions (positive scale item \[P\] 1), unusual thought content (general scale item \[G\] 9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (negative scale item \[N\] 1), passive/apathetic social withdrawal (N4), and lack of spontaneity and conversation flow (N6). Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). Percentage of participants achieving remission was determined by LOCF method.

    Time frame: Up to 6 weeks

  4. Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score

    The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6-17 years and provides a global measure of the severity of disturbance. The scale is separated into 10-point sections that are headed with a description of the level of functioning and followed by examples matching the interval. The score ranges from 0-100, 1 to 10 indicates the need for constant supervision and 91 to 100 indicates superior functioning in all areas. Higher scores indicate better functioning. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

    Time frame: Baseline to Week 6

  5. Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score

    The CGI-S scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 to 7. The investigator answered the question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?". Response choices were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Higher scores indicate worse condition. LS mean was determined by the MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

    Time frame: Baseline to Week 6

  6. Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6

    The efficacy of brexpiprazole in the treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was entirely due to drug treatment on a 7-point scale, ranging from 0 to 7. Response choices were: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Higher scores indicate worse condition. Mean CGI-I scale score was determined by LOCF method.

    Time frame: Week 6

  7. Number of Participants With Adverse Events (AEs) and Trial Discontinuation Due to AEs

    An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment.

    Time frame: From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)

  8. Number of Participants With Treatment-emergent AEs (TEAEs), Serious TEAEs, and TEAEs Graded by Severity

    An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE was any AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions which is fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. TEAE is any AE after the start of treatment or if the event was continuous from baseline, medicinal product related, or resulted in death, discontinuation, interruption or reduction of medicinal product. TEAEs were graded on a 3-point scale: 1 (Mild: Discomfort noticed, but no disruption to daily activity), 2 (Moderate: Discomfort sufficient to reduce or affect normal daily activity), and 3 (Severe: Inability to work or perform normal daily activity).

    Time frame: From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)

  9. Mean Change From Baseline in Weight

    Change in weight was reported, in kilograms (kg).

    Time frame: Baseline up to last visit (approximately 6 weeks)

  10. Mean Change From Baseline in Height

    Change in height was reported in centimeters (cm).

    Time frame: Baseline up to last visit (approximately 6 weeks)

  11. Mean Change From Baseline in Body Mass Index (BMI)

    Change in BMI was reported in kilograms per square meter (kg/m\^2).

    Time frame: Baseline up to last visit (approximately 6 weeks)

  12. Mean Change From Baseline in Waist Circumference

    Change in waist circumference was reported in 'cm'.

    Time frame: Baseline up to last visit (approximately 6 weeks)

  13. Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a scale used to report at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any of the following items: actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior. The suicidal ideation total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) and the total score ranges from 0 to 25. Lower scores indicate improvement.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

  14. Number of Participants With Potentially Clinically Relevant Laboratory Test Values

    Potentially clinically relevant laboratory values assessed included - serum chemistry \[including blinded prolactin\], hematology, and urinalysis as defined in SAP.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

  15. Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs

    Vital sign measurements included body weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood pressure measurements were made in the supine, sitting, and standing positions after the participant had been in each position for at least 3 minutes as defined in SAP.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

  16. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

    Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes as defined in SAP.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

  17. Change From Baseline in Simpson Angus Scale (SAS) Total Score

    The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where lower scores indicate less severe condition. LS mean was determined by Analysis of Covariance (ANCOVA) model with treatment and study center as main effects and baseline value as covariate.

    Time frame: Baseline up to last visit (approximately 6 weeks)

  18. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

    The AIMS assessment consists of 12 items rating the involuntary movements: Facial and oral movements (4 items), extremity movements (2 items), and trunk movements (1 item) were observed unobtrusively while the participant is at rest and the investigator also made global judgments on the participant's dyskinesias (2 items), and dental status (2 items). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). Total Score is the sum of the scores of all 12 items, ranging from 0 to 48, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.

    Time frame: Baseline up to last visit (approximately 6 weeks)

  19. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score

    The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.

    Time frame: Baseline up to last visit (approximately 6 weeks)

  20. Number of Participants With Severe Psychotropic Side Effects as Assessed by Udvalg for Kliniske Undersogelser (UKU) Rating Scale

    The UKU rating scale is a semi-structured interview used to assess the side effects of participants being treated with antipsychotic drugs. The scale is divided into 6 sub-scales: Psychic, neurological, autonomic, other, global assessment by subject, and global assessment by doctor. The scale has a total of 48 items, each item is rated on a 4-point scale (0=not present; 1=mild; 2=moderate; 3=severe), and the total score ranges from 0 to 144. Higher ratings indicate greater impairment. The severe side effects are reported in this outcome measure.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

  21. Number of Participants With Cognitive Adverse Effects Assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)

    The NY-AACENT is used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems, specifically designed to be used in pediatric population (ages 12 to 17), but could have been utilized with other age groups, as appropriate. Number of participants with at least one occurrence of the corresponding signs/symptoms are reported in this outcome measure.

    Time frame: From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)

07

Results

Posted Dec 20, 2023

Participant flow

Participants took part in the study at investigational sites in the United States, Mexico, France, Italy, Poland, Romania, Serbia, Spain, Ukraine, and Russia from 30 June 2017 to 03 April 2023.

Participant flow — Overall Study
MilestoneBrexpiprazoleAripiprazolePlacebo
Started110102104
Safety sample110102104
Efficacy sample110101103
Completed1079792
Not completed3512
Withdrew: Adverse event012
Withdrew: Lack of efficacy003
Withdrew: Lost to follow-up100
Withdrew: Pregnancy010
Withdrew: Withdrawal by subject102
Withdrew: Withdrawal by caregiver135

Outcome measures

PrimaryChange From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) to 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranges from 30 (best possible outcome) to 210 (worst possible outcome). Higher scores indicate worsening of symptoms. Least squares (LS) mean was determined by Mixed-effect model repeated measures (MMRM) method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value and baseline visit interaction as a covariate, and with an unstructured covariance.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score-22.75 ± 1.49-23.95 ± 1.57-17.42 ± 1.58
Statistical analysis
  • Brexpiprazole vs Placebo · MMRM · p = 0.0136 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -5.33 · 95% CI -9.55 to -1.10
  • Aripiprazole vs Placebo · MMRM · p = 0.0032 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -6.53 · 95% CI -10.8 to -2.21
SecondaryChange From Baseline to Week 6 in PANSS Positive and Negative Sub-Scales Scores

PANSS has 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, hostility; and 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). PANSS positive \& negative subscale scores were the sum of rating scores for 7 positive \& 7 negative items respectively. Both scores range from 7 (best possible outcome) to 49 (worst possible outcome). Higher scores denote worsening of symptoms. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in PANSS Positive and Negative Sub-Scales Scores
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline to Week 6 in PANSS Positive Sub-scale Score-6.58 ± 0.43-7.29 ± 0.45-5.14 ± 0.46
Change From Baseline to Week 6 in PANSS Negative Sub-scale Score-4.70 ± 0.41-4.77 ± 0.43-3.82 ± 0.44
Statistical analysis
  • Brexpiprazole vs Placebo · MMRM · p = 0.0205 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -1.44 · 95% CI -2.65 to -0.22
  • Aripiprazole vs Placebo · MMRM · p = 0.0008 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -2.15 · 95% CI -3.40 to -0.91
  • Brexpiprazole vs Placebo · MMRM · p = 0.1360 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -0.88 · 95% CI -2.04 to 0.28
  • Aripiprazole vs Placebo · MMRM · p = 0.1158 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -0.95 · 95% CI -2.14 to 0.24
SecondaryPercentage of Participants Achieving Response

Response was defined as at least 30% improvement from baseline in PANSS Total Score or CGI score of 1 or 2. The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel, and ranges from 30 (best possible outcome) to 210 (worst possible outcome). The CGI scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Percentage of participants achieving response was determined by Last Observation Carried Forward (LOCF) method.

Time frame:
Up to 6 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Response
percentage of participantsBrexpiprazoleAripiprazolePlacebo
Percentage of Participants Achieving Response43.6443.5628.16
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0111 · Ratio of response rate: 1.55 · 95% CI 1.09 to 2.20P-value was analyzed by Cochran-Mantel-Haenszel (CMH) general association test controlling for (pooled) centers.
  • Aripiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0224 · Ratio of response rate: 1.51 · 95% CI 1.06 to 2.16P-value was analyzed by CMH general association test controlling for (pooled) centers.
SecondaryPercentage of Participants Achieving Remission

Remission was defined as a score of ≤ 3 on each of the following specific PANSS items: delusions (positive scale item \[P\] 1), unusual thought content (general scale item \[G\] 9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerisms/posturing (G5), blunted affect (negative scale item \[N\] 1), passive/apathetic social withdrawal (N4), and lack of spontaneity and conversation flow (N6). Each item's severity was rated on 7-point scale, with score of 1 (absence of symptoms) to 7 (extremely severe symptoms). Percentage of participants achieving remission was determined by LOCF method.

Time frame:
Up to 6 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission
percentage of participantsBrexpiprazoleAripiprazolePlacebo
Percentage of Participants Achieving Remission29.0935.6423.30
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.4415 · Ratio of remission rate: 1.18 · 95% CI 0.77 to 1.81P-value was analyzed by CMH general association test controlling for (pooled) centers.
  • Aripiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0472 · Ratio of remission rate: 1.48 · 95% CI 1.01 to 2.16P-value was analyzed by CMH general association test controlling for (pooled) centers.
SecondaryChange From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score

The CGAS is a 100-point rating scale measuring psychological, social, and school functioning for children aged 6-17 years and provides a global measure of the severity of disturbance. The scale is separated into 10-point sections that are headed with a description of the level of functioning and followed by examples matching the interval. The score ranges from 0-100, 1 to 10 indicates the need for constant supervision and 91 to 100 indicates superior functioning in all areas. Higher scores indicate better functioning. LS mean was determined by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline to Week 6 in Children's Global Assessment Scale (CGAS) Total Score10.56 ± 1.0012.07 ± 1.058.08 ± 1.06
Statistical analysis
  • Brexpiprazole vs Placebo · MMRM · p = 0.0854 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: 2.48 · 95% CI -0.35 to 5.31
  • Aripiprazole vs Placebo · MMRM · p = 0.0072 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: 3.99 · 95% CI 1.09 to 6.88
SecondaryChange From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score

The CGI-S scale is an investigator-rated evaluation that assesses the severity of a participant's illness on a 7-point scale, ranging from 1 to 7. The investigator answered the question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?". Response choices were: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Higher scores indicate worse condition. LS mean was determined by the MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline to Week 6 in Clinical Global Impression Severity (CGI-S) Scale Score-0.92 ± 0.09-1.01 ± 0.09-0.80 ± 0.09
Statistical analysis
  • Brexpiprazole vs Placebo · MMRM · p = 0.3589 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -0.11 · 95% CI -0.36 to 0.13
  • Aripiprazole vs Placebo · MMRM · p = 0.1118 (P-value was analyzed by MMRM method with fixed effect of treatment, (pooled) clinical center visit, treatment visit interaction, baseline value, and baseline visit interaction as a covariate, and with an unstructured covariance.) · Ls mean difference: -0.20 · 95% CI -0.45 to 0.05
SecondaryMean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6

The efficacy of brexpiprazole in the treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was entirely due to drug treatment on a 7-point scale, ranging from 0 to 7. Response choices were: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Higher scores indicate worse condition. Mean CGI-I scale score was determined by LOCF method.

Time frame:
Week 6
Reported as:
Mean · score on a scale
Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 6
score on a scaleBrexpiprazoleAripiprazolePlacebo
Mean Clinical Global Impression Improvement (CGI-I) Scale Score at Week 62.86 ± 0.952.79 ± 0.973.17 ± 1.08
Statistical analysis
  • Brexpiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0287 · Mean difference (final values): -0.29 · 95% CI -0.56 to -0.03P-value was analyzed by CMH row mean scores differ test controlling for study center.
  • Aripiprazole vs Placebo · Cochran-Mantel-Haenszel · p = 0.0184 · Mean difference (final values): -0.34 · 95% CI -0.62 to -0.06P-value was analyzed by CMH row mean scores differ test controlling for study center.
SecondaryNumber of Participants With Adverse Events (AEs) and Trial Discontinuation Due to AEs

An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment.

Time frame:
From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Trial Discontinuation Due to AEs
ParticipantsBrexpiprazoleAripiprazolePlacebo
AEs465644
Trial Discontinuation Due to AEs012
SecondaryNumber of Participants With Treatment-emergent AEs (TEAEs), Serious TEAEs, and TEAEs Graded by Severity

An AE was defined as any untoward medical occurrence in a participant administered with a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE was any AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions which is fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. TEAE is any AE after the start of treatment or if the event was continuous from baseline, medicinal product related, or resulted in death, discontinuation, interruption or reduction of medicinal product. TEAEs were graded on a 3-point scale: 1 (Mild: Discomfort noticed, but no disruption to daily activity), 2 (Moderate: Discomfort sufficient to reduce or affect normal daily activity), and 3 (Severe: Inability to work or perform normal daily activity).

Time frame:
From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent AEs (TEAEs), Serious TEAEs, and TEAEs Graded by Severity
ParticipantsBrexpiprazole 2 to 4 mg/DayAripiprazole 10 to 20 mg/DayPlacebo
TEAEs445342
Serious TEAEs113
Mild TEAEs334732
Moderate TEAEs171613
Severe TEAEs201
SecondaryMean Change From Baseline in Weight

Change in weight was reported, in kilograms (kg).

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Mean · kg
Mean Change From Baseline in Weight
kgBrexpiprazoleAripiprazolePlacebo
Mean Change From Baseline in Weight0.8 ± 2.60.5 ± 2.70.0 ± 2.2
SecondaryMean Change From Baseline in Height

Change in height was reported in centimeters (cm).

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Mean · cm
Mean Change From Baseline in Height
cmBrexpiprazoleAripiprazolePlacebo
Mean Change From Baseline in Height0.2 ± 1.10.2 ± 2.90.3 ± 0.6
SecondaryMean Change From Baseline in Body Mass Index (BMI)

Change in BMI was reported in kilograms per square meter (kg/m\^2).

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Mean · kg/m^2
Mean Change From Baseline in Body Mass Index (BMI)
kg/m^2BrexpiprazoleAripiprazolePlacebo
Mean Change From Baseline in Body Mass Index (BMI)0.2 ± 1.10.3 ± 1.50.0 ± 0.9
SecondaryMean Change From Baseline in Waist Circumference

Change in waist circumference was reported in 'cm'.

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Mean · cm
Mean Change From Baseline in Waist Circumference
cmBrexpiprazoleAripiprazolePlacebo
Mean Change From Baseline in Waist Circumference0.6 ± 3.9-0.3 ± 4.30.0 ± 5.1
SecondaryNumber of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a scale used to report at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any of the following items: actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior. The suicidal ideation total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) and the total score ranges from 0 to 25. Lower scores indicate improvement.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsBrexpiprazoleAripiprazolePlacebo
Number of Participants With At Least One Occurrence of Suicidal Behavior or Suicidal Ideation as Recorded on Columbia-Suicide Severity Rating Scale (C-SSRS)122
SecondaryNumber of Participants With Potentially Clinically Relevant Laboratory Test Values

Potentially clinically relevant laboratory values assessed included - serum chemistry \[including blinded prolactin\], hematology, and urinalysis as defined in SAP.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Laboratory Test Values
ParticipantsBrexpiprazoleAripiprazolePlacebo
Alanine Aminotransferase (U/L): High120
Bilirubin (mg/dL): High010
Cholesterol, Fasting (mg/dL): High230
Creatine kinase (U/L): High541
Glucose, Fasting (mg/dL): High16159
HDL Cholesterol, Fasting (mg/dL): Low121013
LDL Cholesterol, Fasting (mg/dL): High230
Triglycerides, Fasting (mg/dL): High13710
Urate (mg/dL): High001
Eosinophils/Leukocytes (%): High200
Hematocrit (%): Low401
Hemoglobin (g/dL): Low200
Leukocytes (10^9/L): Low010
Leukocytes (10^9/L): High001
Protein, Urine: High220
SecondaryNumber of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs

Vital sign measurements included body weight, systolic blood pressure (SBP), and diastolic blood pressure (DBP). Blood pressure measurements were made in the supine, sitting, and standing positions after the participant had been in each position for at least 3 minutes as defined in SAP.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
ParticipantsBrexpiprazoleAripiprazolePlacebo
SBP Sitting (mmHg): Low001
SBP Standing (mmHg): Low110
SBP Supine (mmHg): Low001
DBP Standing (mmHg): Low100
DBP Supine (mmHg): Low010
Weight (kg): Low524
Weight (kg): High955
Orthostatic Hypotension (mmHg): Low212
SecondaryNumber of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes as defined in SAP.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
ParticipantsBrexpiprazoleAripiprazolePlacebo
Rate: Bradycardia001
Rhythm: Sinus Bradycardia001
Rhythm: Supraventricular Premature Beat011
Rhythm: Ventricular Premature Beat100
ST/T Morphology: QTcF010
ST/T Morphology: QTcN010
SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score

The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where lower scores indicate less severe condition. LS mean was determined by Analysis of Covariance (ANCOVA) model with treatment and study center as main effects and baseline value as covariate.

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline in Simpson Angus Scale (SAS) Total Score0.04 ± 0.120.15 ± 0.12-0.03 ± 0.13
Statistical analysis
  • Brexpiprazole vs Placebo · Ls mean difference: 0.07 · 95% CI -0.24 to 0.39LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
  • Aripiprazole vs Placebo · Ls mean difference: 0.18 · 95% CI -0.14 to 0.51LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score

The AIMS assessment consists of 12 items rating the involuntary movements: Facial and oral movements (4 items), extremity movements (2 items), and trunk movements (1 item) were observed unobtrusively while the participant is at rest and the investigator also made global judgments on the participant's dyskinesias (2 items), and dental status (2 items). Severity of each item was rated on a 5-point scale, with a score of 0 (absence of symptoms) to 4 (severe condition). Total Score is the sum of the scores of all 12 items, ranging from 0 to 48, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score-0.12 ± 0.090.05 ± 0.09-0.06 ± 0.09
Statistical analysis
  • Brexpiprazole vs Placebo · Ls mean difference: -0.06 · 95% CI -0.30 to 0.18LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
  • Aripiprazole vs Placebo · Ls mean difference: 0.11 · 95% CI -0.13 to 0.36LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Score

The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14, higher scores indicate severe condition. LS mean was determined by ANCOVA model with treatment and study center as main effects and baseline value as covariate.

Time frame:
Baseline up to last visit (approximately 6 weeks)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
score on a scaleBrexpiprazoleAripiprazolePlacebo
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score0.01 ± 0.030.06 ± 0.030.01 ± 0.03
Statistical analysis
  • Brexpiprazole vs Placebo · Ls mean difference: 0.00 · 95% CI -0.08 to 0.09LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
  • Aripiprazole vs Placebo · Ls mean difference: 0.05 · 95% CI -0.04 to 0.14LS mean difference was analyzed by ANCOVA model, with treatment and study center as main effects and baseline value as covariate.
SecondaryNumber of Participants With Severe Psychotropic Side Effects as Assessed by Udvalg for Kliniske Undersogelser (UKU) Rating Scale

The UKU rating scale is a semi-structured interview used to assess the side effects of participants being treated with antipsychotic drugs. The scale is divided into 6 sub-scales: Psychic, neurological, autonomic, other, global assessment by subject, and global assessment by doctor. The scale has a total of 48 items, each item is rated on a 4-point scale (0=not present; 1=mild; 2=moderate; 3=severe), and the total score ranges from 0 to 144. Higher ratings indicate greater impairment. The severe side effects are reported in this outcome measure.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Severe Psychotropic Side Effects as Assessed by Udvalg for Kliniske Undersogelser (UKU) Rating Scale
ParticipantsBrexpiprazoleAripiprazolePlacebo
Psychic: Concentration Difficulties7108
Psychic: Asthenia/Lassitude631
Psychic: Failing Memory224
Psychic: Depression021
Psychic: Tension/Inner Unrest439
Psychic: Increased Duration of Sleep010
Psychic: Reduced Duration of Sleep411
Psychic: Increased Dream Activity020
Psychic: Emotional Indifference366
Neurologic: Akathisia110
Autonomic: Nausea/Vomiting001
Autonomic: Micturition Disturbances010
Autonomic: Palpitations/Tachycardia101
Autonomic: Increased Tendency to Sweating100
Other: Weight Gain010
Other: Amenorrhoea010
Other: Migraine001
SecondaryNumber of Participants With Cognitive Adverse Effects Assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)

The NY-AACENT is used to detect changes in cognitive function subsequent to pharmacological or similar treatments for neurological or psychiatric problems, specifically designed to be used in pediatric population (ages 12 to 17), but could have been utilized with other age groups, as appropriate. Number of participants with at least one occurrence of the corresponding signs/symptoms are reported in this outcome measure.

Time frame:
From the first dose of study drug up to last dose of study drug (up to approximately 6 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Cognitive Adverse Effects Assessed by New York Assessment for Adverse Cognitive Effects of Neuropsychiatric Treatment (NY-AACENT)
ParticipantsBrexpiprazoleAripiprazolePlacebo
Working Memory887983
Attention/Vigilance989091
Verbal Learning717069
Visual Learning464644
Reasoning978683
Speed of Processing888482
Social Cognition918784
Any Signs/Symptoms1009192

Adverse events

Collected over From the first dose of study drug up to 21 days after the last dose of study drug (up to approximately 9 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole0/110 (0%)1/110 (0.9%)19/110 (17.3%)
Aripiprazole0/102 (0%)1/102 (1%)28/102 (27.5%)
Placebo0/104 (0%)3/104 (2.9%)16/104 (15.4%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazoleAripiprazolePlacebo
SchizophreniaPsychiatric disorders1/1100/1022/104
Psychotic DisorderPsychiatric disorders0/1101/1021/104
Most frequent other events
Most frequent other events
EventBrexpiprazoleAripiprazolePlacebo
SomnolenceNervous system disorders5/11011/1025/104
FatigueGeneral disorders2/1108/1020/104
AkathisiaNervous system disorders4/1107/1023/104
NauseaGastrointestinal disorders7/1104/1024/104
HeadacheNervous system disorders7/1105/1025/104

Baseline characteristics

Randomized sample included all participants who were randomized into the trial.

Age, Continuous
Age, Continuous(years)BrexpiprazoleAripiprazolePlaceboTotal
Mean15.3 ± 1.515.3 ± 1.415.2 ± 1.415.3 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)BrexpiprazoleAripiprazolePlaceboTotal
Female585751166
Male524553150
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BrexpiprazoleAripiprazolePlaceboTotal
Race — White706668204
Race — Black or African American87621
Race — American Indian or Alaska Native2147
Race — Asian1102
Race — Other29272581
Race — Missing0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BrexpiprazoleAripiprazolePlaceboTotal
Ethnicity — Hispanic or Latino343234100
Ethnicity — Not Hispanic or Latino757068213
Ethnicity — Other1012
Ethnicity — Missing0011
Region of Enrollment
Region of Enrollment(participants)BrexpiprazoleAripiprazolePlaceboTotal
United States15141443
France0011
Italy1113
Mexico32313295
Poland53311
Romania66618
Russia44311
Serbia11101031
Spain1001
Ukraine353334102
Positive and Negative Syndrome Scale (PANSS) Total Score
Positive and Negative Syndrome Scale (PANSS) Total Score(score on a scale)BrexpiprazoleAripiprazolePlaceboTotal
Mean101.1 ± 14.9101.0 ± 13.0102.1 ± 16.3101.4 ± 14.7
08

Study locations

1 site
  • For additional information regarding sites, contact 844-687-8522
    Oklahoma City, Oklahoma 73116, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Apr 2023, 69 months.

Results were first posted in Dec 2023, 8 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 69 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Jun 23, 2017
StartActual
Jun 30, 2017
Primary completionActual
Apr 3, 2023
CompletionActual
Apr 3, 2023
Results first posted
Dec 20, 2023
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03198078
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 23, 2017
Start date
Jun 30, 2017
Primary completion
Apr 3, 2023
Completion
Apr 3, 2023
Results posted
Dec 20, 2023
Last update
Dec 20, 2023

Study contacts

Caroline Ward, PhD.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion